This means that a large subpopulation of CD patients may not benefit from the long-term use of TNF-α monoclonal antibodies because it impedes the host’s ability to effectively mitigate infection, which is, ironically, the causative agent for disease (34–36). This evidence concerns the gene TNF and infection.